News
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...
A shortened, all-oral drug regimen worked well for some patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB ...
Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...
Nicotine vaping continues to outperform FDA-approved smoking cessation therapies in well-designed studies, including a new clinical trial conducted in Australia. This growing body of evidence badly ...
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
2d
ScienceAlert on MSNAncient Killer Is Rapidly Becoming Resistant to Antibiotics, Warns StudyIn spite of having plagued humans for millennia, typhoid fever is rarely considered in developed countries today. But this ancient threat is still very much a danger in our modern world. According to ...
Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC) to develop novel tissue engineering and cell therapy solutions, ...
3d
Zacks Small Cap Research on MSNNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxNNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results